Clinical Trial Update: A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430 [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating single-dose safety, tolerability, and pharmacokinetics of IV BCX4430 for Marburg Virus Disease has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marburg Virus Disease

Drugs mentioned

• BCX4430

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Marburg Virus Disease | Phase 1 | Status: COMPLETED | Results posted: 2021-07-23